Recipharm and Blue Wolf Capital News and Resources

In a significant move that signals the ongoing reshaping of the Contract Development and Manufacturing Organisation (CDMO) industry, Recipharm has sold off seven of its manufacturing and development facilities in Europe. The buyer is the U.S. private equity firm, Blue Wolf Capital.